ADRB2 and cancer: Botta and Maestroni (2008) found that β2-AR antagonism along with TLR2 activation at the site of intradermal cancer vaccination may either enhance the resulting antitumor response or be tolerogenic in dependence of the maturation state of the transferred DC.